Pharmacia patents expiration
1. Caduet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5969156 | PHARMACIA | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126971 | PHARMACIA | Stable oral CI-981 formulation and process for preparing same |
Jan, 2013
(11 years ago) | |
|
US6126971 (Pediatric) | PHARMACIA | Stable oral CI-981 formulation and process for preparing same |
Jul, 2013
(10 years ago) | |
| US5686104 | PHARMACIA | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | PHARMACIA | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
|
US5969156 (Pediatric) | PHARMACIA | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
| US6455574 | PHARMACIA | Therapeutic combination |
Aug, 2018
(5 years ago) | |
Drugs and Companies using AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 29 July, 2004
Treatment: Method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia; Treatment of hypertension and hyperlipidemia with a single composition
Dosage: TABLET;ORAL
CADUET family patents
2. Genotropin Preservative Free patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5501673 | PHARMACIA | Injection cartridge |
Apr, 2013
(11 years ago) | |
| US5435076 | PHARMACIA | Injection device |
Apr, 2013
(11 years ago) | |
| US5716338 | PHARMACIA | Dual-chamber type injection cartridge with bypass connection |
Feb, 2015
(9 years ago) | |
| US6152897 | PHARMACIA | Syringe |
Nov, 2018
(5 years ago) | |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 October, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
GENOTROPIN PRESERVATIVE FREE family patents
3. Somavert patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849535 | PHARMACIA | Human growth hormone variants |
Mar, 2017
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6057292 | PHARMACIA | Method for inhibiting growth hormone action |
Sep, 2015
(8 years ago) | |
Drugs and Companies using PEGVISOMANT ingredient
Market Authorisation Date: 31 July, 2014
Treatment: Acromegaly in patients w/inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom these therapies are not appropriate
Dosage: INJECTABLE;SUBCUTANEOUS
SOMAVERT family patents